MS Stem Cell Therapy Abroad: A Guide for Patients in the Netherlands & UAE
How people living with multiple sclerosis in the Netherlands and the United Arab Emirates can navigate stem cell therapy abroad — with clear context on MSC versus HSCT, regulation at home, travel logistics, and honest expectations.
Why Patients in the Netherlands and UAE Look Abroad
Multiple sclerosis care in the Netherlands is well organised: patients are managed through specialist MS centres and neurology departments, with access to a broad range of licensed disease-modifying therapies (DMTs) and rehabilitation. In the United Arab Emirates, patients in Dubai and Abu Dhabi access high-quality neurology at leading private and government hospitals, again with modern DMTs available.
Despite this, some patients — particularly those with active disease not fully controlled by DMTs, or those seeking to address symptoms and quality of life — research cell-based options that are not part of routine care at home. StemCell Longevita operates as an international patient coordination platform based in Istanbul, Turkey. We are not a treatment provider and we do not replace your neurologist. Our role is to explain the options honestly, assess whether MSC therapy may be a reasonable adjunct in your situation, and coordinate access to GMP-standard care at an accredited partner hospital.
This guide addresses the Dutch and Emirati context directly — the regulatory framework you live under, the important difference between the two very different procedures often both called 'stem cell therapy', and the practical realities of travelling to Istanbul from Schiphol or the Gulf.
MSC vs HSCT: A Crucial Distinction
The single most important thing for any MS patient to understand is that two entirely different procedures are commonly discussed under the umbrella of 'stem cell therapy'. Confusing them leads to unrealistic expectations. We make sure Dutch and UAE patients understand exactly which one is on the table before any decision.
HSCT (aggressive, hospital-based)
- Autologous haematopoietic stem cell transplant — a rebooting of the immune system
- Involves chemotherapy conditioning; carried out in specialist transplant centres
- Strongest evidence in highly active relapsing-remitting MS
- Significant risks and strict eligibility; increasingly studied within trials in Europe
- This is NOT what MSC coordination involves
MSC Therapy (gentler, adjunctive)
- Mesenchymal stem cell infusion — immunomodulatory and supportive in intent
- No chemotherapy; delivered as an outpatient infusion course
- Studied as an adjunctive, quality-of-life-focused option
- Gentler risk profile, but earlier-stage and less definitive evidence
- This is the approach StemCell Longevita coordinates
The Regulatory Picture at Home
Understanding the framework in your country makes the decision to explore treatment abroad an informed one.
Netherlands (EU/EMA)
MSC therapy for MS is not an approved or reimbursed treatment under EMA rules and is not offered within Dutch neurology as routine care. Choosing it abroad is a personal, out-of-pocket decision.
United Arab Emirates
The UAE actively supports regenerative medicine research, but MSC therapy for MS is not a standard approved pathway. Patients typically travel while continuing DMTs prescribed at home.
Turkey's Framework
Turkey regulates cell therapy through its Ministry of Health with GMP-certified processing. MSC therapy for MS is offered within an individually-assessed, adjunctive, non-curative framework.
Honest Positioning
MSC therapy is not a cure for MS and does not replace DMTs. It is best framed as a supportive option for selected patients, with realistic, individually-set expectations.
What MSC Therapy Targets in MS
The rationale under study centres on the immune and inflammatory processes that drive MS.
Immune Modulation
MSCs are studied for their capacity to dampen the autoreactive immune activity that attacks myelin, potentially reducing inflammatory drive.
Neuroprotective Signalling
Through secreted factors, MSCs are being investigated for support of the environment around damaged nerves — a research-stage hypothesis, not established fact.
Symptom-Focused Goals
Reported outcomes in early studies focus on fatigue, quality of life, and function rather than reversal of established disability.
Adjunct, Not Replacement
The intent is to work alongside your disease-modifying therapy, never to justify stopping it. Any DMT changes belong to your neurologist.
The Coordinated Patient Journey
From first enquiry in the Netherlands or UAE to follow-up back home, the process is structured and transparent.
1. Remote Case Review
You share your MS type, MRI reports, EDSS/disability status, and current DMTs. A medical team assesses suitability before anything is booked.
2. Consultation in Your Language
Consultations in English and Dutch, with Arabic-speaking coordination for UAE patients, ensure you fully understand the options.
3. Travel & Treatment Window
A typical stay in Istanbul is 5–7 days, arranged with mobility and fatigue needs in mind.
4. Treatment Episode
Care is delivered at a JCI-accredited partner hospital using GMP-processed cells, with appropriate neurological monitoring.
5. Structured Follow-Up
A 12-month telemedicine follow-up keeps your Dutch or Emirati neurologist informed of exactly what was done.
6. Single Coordinator
One point of contact supports you throughout — valuable when fatigue and mobility make complex logistics harder.
Travel from Amsterdam, Dubai & Abu Dhabi
Istanbul's connectivity to both Northern Europe and the Gulf makes coordinated travel practical. For MS patients, logistics are planned around fatigue management and accessibility.
From the Netherlands
- Direct flights Amsterdam (AMS) to Istanbul (IST): approximately 3.5 hours
- No visa required for Dutch citizens for short medical stays
- Minimal time difference reduces fatigue and disruption
- English and Dutch-speaking coordination throughout
- Accessible transfers and accommodation arranged in advance
From the UAE
- Direct flights Dubai (DXB) & Abu Dhabi (AUH) to Istanbul: approximately 4.5 hours
- Straightforward entry for UAE residents and citizens
- One hour behind UAE time — easy adjustment
- Arabic-speaking coordination support available
- Wheelchair-accessible transfers and family accommodation on request
Cost Compared to Staying Home
Indicative figures only — every case is individually quoted after medical review confirms suitability.
Working With Your Neurologist
MSC therapy should complement your established MS care in the Netherlands or UAE — never replace it.
Who Is a Candidate?
Careful selection is essential, and some enquiries are advised that treatment is not appropriate.
Frequently Asked Questions
Related Stem Cell Treatments
Explore Care Coordination for Your Country
Trattamenti correlati
Malattia di Parkinson
Mira a rallentare la progressione e a sostenere i neuroni che producono dopamina.
Scopri di piùSclerosi multipla
Mira a regolare la risposta immunitaria e a sostenere la salute della guaina mielinica.
Scopri di piùTerapia per l'autismo
Può sostenere la funzione neurologica e ridurre l'infiammazione.
Scopri di piùCoordinamento Internazionale dei Pazienti
StemCell Longevita opera come piattaforma di coordinamento internazionale dei pazienti. Mettiamo in contatto i pazienti con istituzioni mediche autorizzate che offrono applicazioni di medicina rigenerativa dopo valutazione medica e nel rispetto dei quadri normativi applicabili. Tutte le decisioni e le procedure mediche sono condotte esclusivamente da professionisti sanitari autorizzati. StemCell Longevita non fornisce direttamente trattamenti medici.
Medical Disclaimer
The information provided on this website is for educational and informational purposes only and is not intended as medical advice. Stem cell therapy is an evolving field, and outcomes may vary by individual. The treatments described on this site have not been fully evaluated or approved by the FDA or equivalent regulatory bodies in all jurisdictions.
The FDA has not approved stem cell applications for most conditions listed on this website. Results mentioned are based on clinical observations, published research, and patient-reported outcomes. Individual results may vary and no specific outcomes are assured for any individual patient.
L'inclusione di pubblicazioni scientifiche su questo sito non implica approvazione normativa o risultati clinici garantiti. Alcune applicazioni possono essere considerate sperimentali a seconda dell'indicazione e della giurisdizione.
Always consult with a qualified healthcare professional before making any medical decisions. Do not disregard professional medical advice or delay seeking treatment based on information found on this website.